Bone Biologics Corp
Develops a protein-based bone graft substitute for spinal fusion procedures.
BBLG | US
Overview
Corporate Details
- ISIN(s):
- US0980703039 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 2 BURLINGTON WOODS DRIVE,, 1803 BURLINGTON
- Website:
- https://www.bonebiologics.com/
- Sector:
- Manufacturing
Description
Bone Biologics Corp. is a medical device company focused on developing therapeutics for bone regeneration. The company's core technology is NELL-1, a proprietary recombinant human protein growth factor designed to enhance orthopedic care. Its lead product candidate, NB1, combines rhNELL-1 with a demineralized bone matrix to function as a bone graft substitute. The primary application for NB1 is in spinal fusion procedures, aiming to provide rapid, specific, and guided bone regeneration. Preclinical studies suggest NELL-1 enhances both the quantity and quality of bone, accelerates healing, and forms bone only in targeted areas without causing inflammation or unwanted bone formation. The company is conducting a pilot clinical study for NB1 in spine fusion patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Bone Biologics Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Bone Biologics Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Bone Biologics Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
